Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Yonina R. Murciano‐Goroff(Memorial Sloan Kettering Cancer Center), Emiliano Cocco(University of Miami)

Clinical and Translational Medicine

May 1, 2025

10.1002/ctm2.70338

Cited by 2

Related Papers

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor

|BMC Cancer|2011|47

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

|British Journal of Cancer|2016|42

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

|Cancer Research|2023|37